SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

RAGE GUY (RAGE) is a cryptocurrency inspired by the Rage Guy meme, one of the earliest and most recognizable characters from internet rage comics. The project captures the cultural legacy of early meme history and brings it onto the blockchain in tokenized form. It is designed as a community-driven digital asset that celebrates internet culture, nostalgia, and the role memes play in shaping online communities.

Rage Guy

The RAGE crypto community is rallying behind the project with intense conviction, emphasizing long-term 'bagworking' and the creation of OG-style rage comics to drive mindshare. Investors are actively pushing to secure a top market position while warning against copycat tickers and urging others to join their grassroots effort before a potential breakout.

Melania memes are digital collectibles intended to function as an expression of support for and engagement with the values embodied by the symbol MELANIA

Melania Trump

The Melania Crypto token is actively being labeled by the community as a major pump-and-dump scheme, with discussions centering on the massive losses sustained by retail investors compared to the significant profits reportedly realized by insiders and organizers. Many users are using the symbol as a venue to vent political frustrations and share concerns about the perceived grifting tactics associated with the Trump family's various crypto and media ventures.

Celcuity, Inc. operates as a cellular analysis company. The company discovers new cancer sub-types and commercializing diagnostic tests designed to improve the clinical outcomes of cancer patients treated with targeted therapies. The firm's proprietary CELx diagnostic platform is the commercially ready technology that uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the targeted therapy that treats it. The company was founded by Brian F. Sullivan and Lance G. Laing in January 2012 and is headquartered in Minneapolis, MN.

Celcuity Inc

Celcuity is trending following the publication of positive Phase 3 VIKTORIA-1 trial data, which demonstrated significant survival benefits for its investigational breast cancer drug, gedatolisib. Investors are actively discussing the potential for an accelerated FDA approval timeline, the strategic implications of a recent capital raise, and the stock's long-term value as a potential first-in-class standard of care.

Fabrinet engages in the provision of optical packaging and electronic manufacturing services to original equipment manufacturers. The firm's engineering services include process design, failure analysis, reliability testing, tooling design, and real-time traceability system. Its manufacturing operations offer sensors, subsystems, customized optics, and optical modules and components. The company was founded by David Thomas Mitchell on August 12, 1999 and is headquartered in George Town, Cayman Islands.

Fabrinet

Fabrinet is currently trending as investors closely monitor its role in the AI-driven data center and optical packaging sector, with community sentiment divided between excitement over long-term growth and caution regarding valuation and potential supply chain shifts. Discussion is heavily focused on the company's recent earnings performance, its strategic importance as a manufacturer for major tech partners, and its ability to sustain momentum amid sector volatility.

Amgen, Inc. is a biotechnology company, which engages in the discovery, development, manufacture, and marketing of human therapeutics. The company was founded by William K. Bowes, Jr., Franklin Pitcher Johnson, Jr., George B. Rathmann, and Joseph Rubinfeld on April 8, 1980 and is headquartered in Thousand Oaks, CA.

AMGEN Inc.

Amgen is gaining institutional momentum ahead of its upcoming earnings as investors rotate out of technology and into resilient healthcare names, while the company leverages a robust portfolio of mature drugs and late-stage pipeline assets to navigate competitive pricing pressures. Market participants are closely watching the company's capital allocation strategy and manufacturing expansion efforts, which are being bolstered by favorable policy developments and a strengthening competitive position in the cardiovascular and inflammatory disease markets.

Ecopetrol SA engages in the exploration, development, and production of crude oil and natural gas. It operates through the following segments: Exploration and Production, Transportation and Logistics, and Refining and Petrochemicals. The Exploration and Production segment deals with oil and gas exploration and production activities. The Transportation and Logistics segment comprises of pipelines and other transportation activities. The Refining and Petrochemicals segment involves in refining activities and its products include motor fuels, fuel oils, and petrochemicals. The company was founded in 1948 and is headquartered in Bogota, Colombia.

Ecopetrol SA - ADR

Ecopetrol SA

Ecopetrol is trending as investors weigh its potential as an undervalued energy play with a strong dividend yield against ongoing geopolitical risks in Colombia and shifting global oil market dynamics. The community is actively debating the stock's long-term outlook, focusing on the company's operational resilience and the impact of political developments on its future growth.

Barclays Bank Plc engages in providing commercial banking services. It offers personal, premier, business, and corporate banking products and services to its customers. Its services include current accounts, savings, investments, mortgages, loans, insurance, credit cards, and online banking. The company was founded on October 4, 1971 and is headquartered in London, the United Kingdom.

Barclays Bank PLC - iPathÂ® Series B S&P 500Â® VIX Short-Term FuturesTM ETN

iPath S&P 500 VIX Short-Term Futures ETN

Investors are closely watching the iPath S&P 500 VIX Short-Term Futures ETN (VXX) as market participants debate whether extreme volatility-shorting behavior signals a major market peak or continued complacency. Community discussion is currently fixated on whether the recent compression in volatility indices, coupled with macroeconomic uncertainty, is setting the stage for a significant capitulatory event or another aggressive melt-up.

SharonAI Holdings, Inc. engages in providing high-performance computing (HPC), artificial intelligence (AI), and cloud GPU compute infrastructure technologies. The company was founded on December 30, 2024 and is headquartered in New York, NY.

SharonAI Holdings Inc. - Ordinary Shares - Class A

SharonAI Holdings is capturing investor attention due to speculation regarding its short-squeeze potential and optimism surrounding its strategic AI partnerships. Community discussions are heavily focused on the stock's low float and aggressive roadmap, leading to polarized debates over whether the momentum represents a long-term growth opportunity or a volatile trading setup.

Direxion Shares ETF Trust - Direxion Daily Energy Bull 2X ETF

Direxion Daily Energy Bull 2X Shares

The Direxion Daily Energy Bull 2X Shares (ERX) is experiencing significant attention as traders and analysts debate the sector's outlook amid ongoing geopolitical tensions, supply fluctuations, and shifting sentiment regarding energy demand. Investors are actively tracking institutional flow and sector gauge signals to navigate the fund's volatility while discussing the potential impact of global macroeconomic policy on crude oil related investments.

Puma Biotechnology, Inc. is a biopharmaceutical company. It acquires and develops innovative products for the treatment of various forms of cancer. It focuses on in-licensing drug candidates that are undergoing or have already completed initial clinical testing for the treatment of cancer and then seek to further develop those drug candidates for commercial use. The company was founded by Alan H. Auerbach on September 15, 2010 and is headquartered in Los Angeles, CA.

Puma Biotechnology Inc

Puma Biotechnology is trending as investors digest its recent NASDAQ Biotechnology Index inclusion and significant developments in its intellectual property lawsuit against AstraZeneca, fueling intense community discussion around its perceived undervaluation, potential for a substantial buyout, and upcoming clinical trial data for its oncology pipeline.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

<ul class="summary-bullets"><li>Roth Capital analyst Boobalan Pachaiyappan recommended buying shares of Capricor Therapeutics on Friday's selloff.</li><li>B. Riley, meanwhile, raised the firm's price target on CAPR to $63 from $50 and kept a ‘Buy’ rating on the shares.</li><li>The Food and Drug Administration has lifted the previously issued Complete Response Letter and resumed the review of the Biologics License Application for Deramiocel with a decision expected by August 22.</li></ul>Shares of Capricor Therapeutics (CAPR) fell 9% on Friday after the company reported a wider-than-expected Q4 loss but Wall Street analysts raised their price targets on the stock over hopes for an approval of the company’s lead candidate.On the company’s fourth-quarter (Q4) <a href="https://stocktwits.com/news-articles/markets/equity/capricor-reports-wider-quaterly-loss-than-expected-but-all-eyes-are-on-deramiocel/cZduNXsRIad">earnings</a> call, CEO Linda Marban <a href="https://stocktwits.com/news-articles/markets/equity/capr-stock-best-week-month-ceo-rules-out-conditional-deramiocel-approval/cZdDdk4RIa1">rejected</a> the possibility that the Deramiocel therapy could receive only a conditional regulatory decision. The U.S. Food and Drug Administration is now expected to rule on Capricor's application for Deramiocel in the treatment of Duchenne Muscular Dystrophy by August 22, 2026, after reversing course on its previous rejection. DMD is a genetic disorder characterized by muscle degeneration.<h2 class="st-heading-2">Wall Street Take Aways</h2>Roth Capital analyst Boobalan Pachaiyappan recommended buying shares of Capricor Therapeutics on today's selloff. The 8% pullback is a "transient, healthy and short-lived market correction" following the rally post FDA acceptance of Capricor's application of Deramiocel for the treatment of Duchenne muscular dystrophy, the analyst told investors in a research note. Roth would be buying today's "dislocation" and expects the share price to move towards its price target of $41. The firm has a ‘Buy’ rating on Capricor.B. Riley, meanwhile, raised the firm's price target on CAPR to $63 from $50 and kept a ‘Buy’ rating on the shares. The analyst said that its confidence has increased in a potential smooth approval path for Deramiocel ahead of the August 22 decision date, with shares expected to build into the decision as investors digest additional dataset, the analyst told investors in a research note.Piper Sandler raised the firm's price target on CAPR to $58 from $45 and kept an ‘Overweight’ rating on the shares. The firm noted Capricor ended 2025 with cash of $318 million to fund operations through 2027. The FDA has lifted the previously issued Complete Response Letter and resumed the review of the Biologics License Application for Deramiocel with a decision expected by August 22. Optimistically, the label could include the broad Duchenne muscular dystrophy population, not just DMD cardiomyopathy, Piper argues.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around CAPR stock remained within the ‘extremely bullish’ territory over the past 24 hours, while message volume remained at ‘extremely high’ levels.<a href="https://stocktwits.com/symbol/CAPR">CAPR stock</a> has gained 138% over the past 12 months.&nbsp;Read More: <a href="https://stocktwits.com/news-articles/markets/equity/tesla-will-delay-release-of-cybercab-until-late-2026-owing-to-safety-issues-fund-manager-predicts/cZdDVgaRIO9">Tesla Will Delay The Release Of Cybercab Until Late-2026 Owing To Safety Issues, Fund Manager Predicts</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the lCapricor Therapeutics logo is seen displayed on the screen of a tablet. (Photo Illustration by Sheldon Cooper/SOPA Images/LightRocket via Getty Images)

CAPR Stock Slumps But Wall Street Reiterates Optimism For Deramiocel Approval

On the company’s fourth-quarter (Q4) earnings call on Thursday, CEO Linda Marban rejected the possibility that the Deramiocel therapy could receive only a conditional approval.

Equity

Eastman Kodak’s shares rallied nearly 12% in extended hours of trading on Thursday after it reported strong growth in its fourth-quarter revenue.&nbsp;Kodak reported consolidated revenues of $290 million in the fourth quarter of 2025, compared with $266 million in the year-ago period, an increase of $24 million or 9%. The rise in revenue was driven by strong performance in Advanced Materials &amp; Chemicals (AM&amp;C) and Print segments.&nbsp;“Kodak ended 2025 with a strong fourth quarter, which has created a foundation for growth in 2026,” said Jim Continenza, Kodak’s Executive Chairman and CEO. “We continue to execute the long-term plan we began in 2019, which focuses on de-levering the company while continuing to invest in our infrastructure and new product innovation”.&nbsp;Kodak ended the year with a cash balance of $337 million, an increase of $136 million from December 31, 2024. The increase was primarily due to the net impact of the Kodak Retirement Income Plan (KRIP) termination and reversion of assets to the company of $153 million.The company reported GAAP net loss of $108 million in Q4 2025, compared with net income of $26 million for Q4 2024. The decline in net income was primarily due to the non-recurring impact of the Kodak Retirement Income Plan ("KRIP") termination and excise tax paid on the reversion of assets to the company.<h2 class="st-heading-2">Retail Reaction</h2>Retail sentiment around KODK stock trended in ‘bullish’ territory amid ‘extremely high’ message volume.&nbsp;One user on Stocktwits called the share rise ‘better than expected’.<stembedurl>https://stocktwits.com/PharmGal/message/647406000</stembedurl>A bullish user said they are optimistic for Kodak in 2026.&nbsp;<stembedurl>https://stocktwits.com/NikkyBenz13/message/647405165</stembedurl>Another bullish user opined that continued growth in Kodak’s Advanced Materials &amp; Chemicals is especially encouraging and could open doors to new markets.&nbsp;<stembedurl>https://stocktwits.com/Judykay/message/647399877</stembedurl>Shares in the company are down 9.4% so far in 2026.&nbsp;For updates and corrections, email newsroom[at]stocktwits[dot]com.&nbsp;

In this photo illustration, the Eastman Kodak Company logo is seen displayed on a smartphone screen.

Eastman Kodak Stock Rallies After-Hours As Q4 Revenue Jumps On Strong Segment Performance

Kodak reported consolidated revenues of $290 million in the fourth quarter of 2025, compared with $266 million in the year-ago period, an increase of $24 million or 9%.

<ul><li>The company reported no revenue for the period, and ended 2025 with cash, cash equivalents, and marketable securities of about $318.1 million.</li><li>Capricor is now awaiting the U.S. Food and Drug Administration’s decision on the application for Deramiocel by August 22.</li><li>The FDA reversed course on its previous rejection for Deramiocel earlier this week.</li></ul>&nbsp;Shares of Capricor Therapeutics (CAPR) slid down about 2% after-hours on Thursday, after the company reported wider-than-expected quarterly loss, partially offset by optimism for the company’s pipeline.For the fourth quarter, the company <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.capricor.com/investors/news-events/press-releases/detail/340/capricor-therapeutics-reports-fourth-quarter-and-full-year">reported</a> a net loss of $0.62 per share, compared to loss of $0.16 per share in the corresponding quarter of 2024, and more than a Wall Street estimate of a loss of $0.54.The company reported no revenue for the period, and ended 2025 with cash, cash equivalents, and marketable securities of about $318.1 million. The company now believes this to be sufficient to cover anticipated expenses and capital requirements though 2027.<h2 class="st-heading-2">Optimism For Deramiocel Application</h2>The company is now awaiting the U.S. Food and Drug Administration’s decision on the application for Deramiocel by August 22. If approved, the company said that its San Diego GMP manufacturing facility will support a potential commercial launch.“Capricor enters 2026 with important regulatory and clinical momentum as we work toward potential approval of Deramiocel for the treatment of Duchenne muscular dystrophy (DMD),” said Linda Marbán, CEO of Capricor.The FDA is now expected to rule on Capricor's application for Deramiocel in the treatment of Duchenne Muscular Dystrophy by August 22, 2026, after reversing course on its previous rejection. DMD is a genetic disorder characterized by muscle degeneration.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around CAPR stock stayed within ‘extremely bullish’ territory over the past 24 hours while message volume remained at ‘extremely high’ levels.<a href="https://stocktwits.com/symbol/CAPR">CAPR stock</a> has gained about 156% over the past 12 months.Read More: <a href="https://stocktwits.com/news-articles/markets/equity/fly-stock-rallies-on-wall-street-spiking-optimism-after-succesful-alpha-launch/cZdujXtRIaP">FLY Stock Rallies On Wall Street’s Spiking Optimism After Successful Alpha Launch</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Capricor Reports Wider Quarterly Loss Than Expected But All Eyes Are On Muscle Disease Therapy

For the fourth quarter, the company reported a net loss of $0.62 per share, compared to loss of $0.16 per share in the corresponding quarter of 2024.

<ul class="summary-bullets"><li>The company swung to profit in Q4 and reported earnings per share of $0.05 versus year-ago loss per share of $0.22.</li><li>Adjusted operating expenses for the fourth quarter of 2025 were $6.5 million compared to $11.9 million for the fourth quarter of 2024.</li><li>On Stocktwits, retail sentiment around DMRC&nbsp;stock trended in ‘extremely bullish’ territory amid ‘high’ message volume.&nbsp;</li></ul>DigiMarc (DMRC) shares rallied 7% during extended hours of trading after it reported a&nbsp;higher-than-expected&nbsp;fourth-quarter (Q4) revenue on Wednesday.&nbsp;DMRC’s total revenue for Q4 2025 was $8.9 million compared to $8.7 million for the fourth quarter of 2024. Analysts on average expected $8.2 million in revenue, as per data from&nbsp;<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="http://fiscal.ai">Fiscal.ai</a>.&nbsp;<h2 class="st-heading-2">Q4 Snapshot</h2>DigiMarc’s subscription revenue for Q4 2025 came at $5.3 million compared to $5.0 million for the fourth quarter of 2024. The increase reflects $1.4 million of patent license fees earned during the quarter and higher subscription revenue from new and existing commercial contracts, partially offset by a $1.4 million decrease relating to the expiration of two previously disclosed commercial contracts in 2025,&nbsp;the company said.The company's adjusted net income for Q4 2025 was $1.0 million or $0.05 per diluted share compared to adjusted net loss of $4.6 million or $0.22 per diluted share for the fourth quarter of 2024.“Digimarc is capitalizing on the convergence of key trends driving increased demand for our solutions, positioning ourselves to benefit from - not be the casualty of - the relentless advance of AI," said Riley McCormack, Digimarc CEO. "In Q4 2025, we achieved both positive non-GAAP net income and positive free cash flow. Looking ahead to 2026, we expect to generate significant ARR growth."<h2 class="st-heading-2">Expenses Come Down</h2>Operating expenses for the quarter were $10.0 million, compared to $14.4 million for Q4 2024.&nbsp;The decrease was led by lower cash compensation costs of $4.4 million, largely due to lower headcount, and lower professional services costs of $0.6 million, partially offset by higher stock compensation costs of $0.7 million.&nbsp;Adjusted operating expenses for the quarter were $6.5 million compared to $11.9 million for Q4 2024.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>Retail sentiment around DMRC&nbsp;stock trended in ‘extremely bullish’ territory amid ‘high’ message volume.&nbsp;Shares in the company have fallen 9.4% so far in 2026.For updates and corrections, email newsroom[at]stocktwits[dot]com.

On Stocktwits, retail sentiment around DMRC stock trended in ‘extremely bullish’ territory amid ‘high’ message volume. 

DigiMarc Stock Rallies After Hours On Q4 Revenue Beat

DMRC’s total revenue for the fourth quarter of 2025 was $8.9 million compared to $8.7 million for the fourth quarter of 2024.

<ul class="summary-bullets"><li>The company said it expects Bumble App Revenue of $171 million to $174 million for Q126.</li><li>In Q4, total revenue decreased 14.3% to $224.2 million, compared to $261.6 million from the year-ago quarter.</li></ul>Shares of Bumble rallied nearly 25% during Wednesday’s extended hours of trading as upbeat outlook for first-quarter revenue cushioned worries from weakness in fourth-quarter earnings.&nbsp;&nbsp;The company said it expects total&nbsp;revenue&nbsp;for Q1 2026 to be in the range of $209 million to $213 million, which includes Bumble App Revenue of $171 million to $174 million. Analysts on average&nbsp;estimate revenue of $210 million.&nbsp;BMBL expects adjusted core profit in the range of $76 million to $80 million for the quarter.<h2 class="st-heading-2">Weak Q4</h2>Total Revenue decreased 14.3% to $224.2 million, compared to $261.6 million from the year-ago quarter. Bumble App revenue also fell 14.8% to $181.0 million, compared to $212.4 million.Bumble’s Total Paying Users slumped 20.5% to 3.3 million, compared to 4.2 million.The company said&nbsp;its fourth quarter net loss was $611.1 million, compared to net earnings of $9.3 million from the year-ago quarter.&nbsp;<h2 class="st-heading-2">FY 2025</h2>In FY2025, Bumble’s total revenue decreased 9.9% to $965.7 million, compared to $1.07 billion. Total Paying Users decreased 11.5% to 3.7 million, compared to 4.1 million.&nbsp;“In 2025, we made the deliberate choice to return Bumble to its women-first foundation, raising the bar on trust and authenticity while addressing pain points our members experience with online dating,” said Whitney Wolfe Herd, Founder &amp; CEO of Bumble Inc.“With the heavy lift of our quality reset behind us, we are accelerating product innovation and prioritizing member experience enhancements. We are building from a stronger base and positioning Bumble for its next chapter of product-led growth,” Herd said.&nbsp;<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>Retail sentiment around BMBL trended in ‘bullish’ territory amid ‘high’ message volume.&nbsp;Shares in BMBL have fallen 2.4% year-to-date.&nbsp;

The exterior of Bumble Headquarters on July 15, 2024 in Austin, Texas. 

Bumble Stock Is Rallying Today After Hours – What Is Causing The Bull Run?

The company said it expects total revenue for Q1 2026 to be in the range of $209 million to $213 million. Analysts on average estimate revenue of $210 million. 

<ul class="summary-bullets"><li>The only drug-related adverse events observed are typically anticipated with gene therapy administration, the company noted.</li><li>It added that a proactive, short-course immune modulation regimen in combination with a differentiated construct and industry-leading product purity levels may contribute to a favorable safety profile for RGX-202.&nbsp;</li><li>Sarepta Therapeutics’s FDA-approved DMD gene therapy Elevidys came under scrutiny last year over concerns of acute liver failure and associated patient deaths.</li></ul>REGENXBIO Inc. (RGNX) on Wednesday announced positive interim data from the company’s early-to-mid stage trial of its gene therapy for Duchenne muscular dystrophy.The investigational gene therapy RGX-202 demonstrated evidence of positively changing disease trajectory for the disease in a few patients enrolled in the trial. It further exhibited a favorable safety profile with no serious adverse events and no evidence of liver injury, the company said.The only drug-related adverse events observed are typically anticipated with gene therapy administration, the company noted, while adding that a proactive, short-course immune modulation regimen in combination with a differentiated construct and industry-leading product purity levels may contribute to a favorable safety profile for RGX-202.Sarepta Therapeutics’s (SRPT) FDA-approved DMD gene therapy, Elevidys, came under scrutiny last year over concerns of acute liver failure and associated patient deaths. Duchenne muscular dystrophy (DMD) is a severe, progressive genetic muscle disease affecting mostly boys.<h2 class="st-heading-2">Application Timeline</h2>REGENXBIO now expects to share topline data from the trial in early second quarter and request a meeting with the FDA in mid-2026, ahead of filing an application seeking approval for the gene therapy.In the meantime, the company will continue to enroll participants for its confirmatory trial, which is expected to have about 30 participants. The company said on Wednesday that it expects to have the majority of the trial enrolled at the time of the application submission.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around RGNX stock fell from ‘extremely bullish’ to ‘bullish’ territory over the past 24 hours, while message volume remained at ‘extremely low’ levels.<a href="https://stocktwits.com/symbol/RGNX">RGNX stock</a> has gained nearly 54% over the past 12 months.&nbsp;Read More: <a href="https://stocktwits.com/news-articles/markets/equity/joby-aviation-makes-first-steps-towards-faa-certification-of-aircraft/cZdrOkARIBb">Joby Aviation Makes First Steps Towards FAA Certification Of Aircraft</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Global stock market chart and trading board - stock photo

Regenxbio Says Its Gene Therapy For Muscle Disorder Showed No Evidence Of Liver Injury In Study 

The investigational gene therapy RGX-202 exhibited a favorable safety profile with no serious adverse events and no evidence of liver injury, the company said. 

<ul class="summary-bullets"><li>The onshore pipelines of SOC have been shut down for a decade since the 2015 Refugio Beach oil spill.</li><li>The efforts come at a time when the U.S.-Israel war with Iran has disrupted global supply of oil and other key energy products.</li><li>Sable in December had said that it received an emergency special permit from PHMSA for Santa Ynez Pipeline System Segments.</li></ul>U.S. President Donald Trump is reportedly set to summon authorities under the Defense Production Act to preempt state laws and ease permitting for Sable Offshore Corp. (SOC)&nbsp; to restart significant production from a cluster of offshore platforms in California.According to a Bloomberg News report, a White House official said that any policy announcement would come directly from the president.&nbsp;The efforts come at a time when the U.S.-Israel war with Iran has disrupted global supply of oil and other key energy products due to the blockade of Strait of Hormuz by Iran.&nbsp;The onshore pipelines have been shut down for a decade since the 2015 Refugio Beach oil spill, when a corroded segment of one pipeline ruptured and released hundreds of thousands of gallons of oil near Santa Barbara.Shares of&nbsp;SOC jumped 18% at the time of writing.&nbsp;&nbsp;<h2 class="st-heading-2">SOC’s Feud</h2>California Attorney General Rob Bonta earlier in the month filed a lawsuit against the Trump Administration, challenging the Pipeline and Hazardous Materials Safety Administration’s (PHMSA) orders that “illegally assert” exclusive jurisdiction over two California onshore oil pipelines of Sable offshore which are known as the Las Flores Pipelines or lines CA-324 and CA-325, and allow them to restart operations.Sable in December had said that it received a receipt of an emergency special permit from PHMSA for Santa Ynez Pipeline System Segments.<h2 class="st-heading-2">IEA Announcement</h2>Earlier in the day, the International Energy Agency announced that all its 32 member countries had unanimously agreed to release 400 million barrels of oil from their emergency reserves to help address disruptions in oil markets caused by the war in the Middle East.Retail sentiment around SOC trended in ‘extremely bullish’ territory amid ‘extremely high’ message volume.&nbsp;Shares in SOC have jumped 59.4% so far in 2026.For updates and corrections, email newsroom[at]stocktwits[dot]com.&nbsp;

A crane ship helps other vessels searching for oil and natural gas near the oil platform offshore the Red Sea in Ras Behar region, Egypt.

Sable Offshore To Reportedly Get Trump Support Via Emergency Law To Restart Production

A White House official said that any policy announcement would come directly from the president, as per a Bloomberg News report. 

<ul class="summary-bullets"><li>Domo also reported EPS of $0.03, while the Street expected the company to post a loss of $0.03 per share.&nbsp;</li><li>Despite the strong results, Lake Street lowered its price target on Domo to $7 from $13 and kept a ‘Hold’ rating on the shares, as per TheFly.&nbsp;</li><li>Cantor Fitzgerald cut the price target on the company to $8 from $13 and maintained an ‘Overweight’ rating on the shares, citing lower overall software multiples.</li></ul>Domo Inc. (DOMO), a cloud software company that leverages artificial intelligence to provide real-time business data to improve executive decision-making, posted fourth-quarter (Q4) results on Tuesday that beat analysts’ expectations.Despite the strong results, Wall Street analysts slashed price targets on the company. Lake Street lowered its price target on Domo to $7 from $13 and kept a ‘Hold’ rating on the shares, as per TheFly.DA Davidson and Cantor Fitzgerald also lowered their price targets on the Utah-based company.<h2 class="st-heading-2">Street Rationale</h2>Lake Street analyst Eric Martinuzzi said the lowered price target reflected a fair takeout price for the growth-challenged SaaS business after the company said in its earnings release that it expects revenue to be flat in FY27 with modest growth in its earnings per share.DA Davidson analyst Lucky Schreiner lowered the price target on Domo to $6 from $10 and kept a ‘Neutral’ rating on the shares. While the firm noted Domo’s strong Q4 results, it said that it is waiting to see more upside to revenue growth prospects before becoming more constructive.Cantor Fitzgerald cut the price target on the company to $8 from $13 and maintained an ‘Overweight’ rating on the shares, citing lower overall software multiples.Based on data from Koyfin, Wall Street has a 12-month average target of $9.58 on Domo shares, representing an upside potential of about 90% compared to the current price levels of $5.04.<h2 class="st-heading-2">Domo Q4 Snapshot</h2>The SaaS company posted a marginal 1% growth in Q4 revenue, coming in at $79.6 million, higher than consensus estimates of $79.03 million. Domo also reported EPS of $0.03, while the Street expected the company to post a loss of $0.03 per share.However, the company refrained from providing specific forward-looking guidance, citing ongoing evaluation of strategic alternatives. The company’s CFO, Tod Crane, however clarified that Domo expects GAAP revenue to remain relatively flat for fiscal year 2027, and modest improvement in non-GAAP EPS and positive adjusted free cash flow.<h2 class="st-heading-2">Retail Sentiment</h2>On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/DOMO">DOMO shares</a> jumped from ‘bullish’ to ‘extremely bullish’ territory over the past 24 hours, while message volumes climbed to ‘extremely high’ levels.Shares of DOMO climbed after the results, and continued to increase on Wednesday. In the past year, DOMO stock has declined more than 37%.Meanwhile, <a href="https://stocktwits.com/symbol/IWM">iShares Russell 2000 ETF</a> (IWM) has climbed by over 25% in the past year, while the <a href="https://stocktwits.com/symbol/VTI">Vanguard Total Stock Market Index Fund ETF</a> (VTI) has gained more than 21%.For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, a US flag is displayed on a smartphone and stock market prices in the background. (Photo Illustration by Romain Doucelin/SOPA Images/LightRocket via Getty Images)

Domo Posted A Double Beat On Q4 Results — So Why Is The Street Slashing Targets?

The cloud software company posted Q4 results on Tuesday, with revenue coming in at $79.6 million, higher than consensus estimates of $79.03 million.

<ul class="summary-bullets"><li>On Stocktwits, retail sentiment around ALDX stock stayed within the ‘bearish’ territory over the past 24 hours, while message volume remained at ‘high’ levels.</li><li>Aldeyra resubmitted its application seeking approval for the drug in July after previous rejections.&nbsp;</li><li>While the agency was initially expected to rule on the application by December, it later extended it until March 16.</li></ul>Shares of Aldeyra Therapeutics (ALDX) garnered retail attention on Stocktwits on Tuesday as the company approaches the date for potential approval of its dry eye treatment Reproxalap.The U.S. Food and Drug Administration (FDA) is slated to rule on the company’s application seeking approval for Reproxalap by March 16. &nbsp;<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around ALDX stock stayed within the ‘bearish’ territory over the past 24 hours, while message volume remained at ‘high’ levels.Users are sharply divided between hopes for approval following a draft label and a recent procedural extension, and concerns over prior rejections.A Stocktwits user expressed optimism for an imminent approval, saying that the FDA has never rejected a drug so many times.<stembedurl>https://www.stocktwits.com/Dragan7/message/647163937</stembedurl>Another expressed hopes for more information as early as Thursday.<stembedurl>https://www.stocktwits.com/UpAndDownUpAndDown/message/647145449</stembedurl><a href="https://stocktwits.com/symbol/ALDX">ALDX stock</a> has dropped 24% over the past 12 months.<h2 class="st-heading-2">Approval Updates</h2>Aldeyra resubmitted its application seeking approval for Reproxalap in July after <a href="https://stocktwits.com/news-articles/markets/equity/aldeyra-therapeutics-stock-slumps-after-fda-letter/chf7PxrRbe1">previous rejections</a>. &nbsp;While the agency was initially expected to rule on the application by December, it later extended it until March 16 to review the additional submissions made by the company as proof of efficacy of its therapy. The company then said that the FDA made no requests or flagged any specific issues with its application review in a meeting in December.Aldeyra first submitted an application to the FDA for Reproxalap in November 2022, but the agency asked for more trials. The company subsequently resubmitted its application in October 2024 but it was rejected in April with the FDA saying the company’s trials failed to demonstrate its efficacy.&nbsp;Read More: <a href="https://stocktwits.com/news-articles/markets/equity/qure-stock-edges-up-after-hours-as-analyst-flags-reduced-regulatory-uncertainty-after-prasad-fda-exit/cZdY5SrRI7s">QURE Stock Edges Up After Hours As Analyst Flags Reduced Regulatory Uncertainty Following Prasad’s FDA Exit</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Aldeyra Therapeutics logo is seen displayed on the screen of a tablet. (Photo Illustration by Sheldon Cooper/SOPA Images/LightRocket via Getty Images)

ALDX Stock Garners Retail Interest: Investors Debate Dry Eye Treatment Approval Amid Long Wait

The U.S. Food and Drug Administration is slated to rule on the company’s application seeking approval for Reproxalap by March 16.  

<ul class="summary-bullets"><li>GRPN’s net income from continuing operations was $8.1 million in the fourth quarter 2025 compared with net loss from continuing operations of $50.1 million in the prior year period.&nbsp;</li><li>The company’s active customers were 16.2 million as of December 31, 2025.</li><li>International gross billings were $122.7 million in the fourth quarter 2025, down 1% year-over-year.&nbsp;</li></ul>Shares of Groupon fell 11% during extended hours of trading on Tuesday after it posted a fourth quarter revenue that fell short of Wall Street expectations.&nbsp;The company said its revenue was $132.7 million in the fourth quarter 2025, up 2% compared with the prior year period. It was below analyst expectations of $136.7 million, as per data from Fiscal.ai.&nbsp;Its net income from continuing operations was $8.1 million in the fourth quarter 2025 compared with net loss from continuing operations of $50.1 million in the prior year period.&nbsp;"Our 2025 results represent a landmark achievement in Groupon’s multi-year transformation, as we returned to growth in both billings and revenue for the first time in a decade," said Dusan Senkypl, CEO of Groupon.The company’s active Customers were 16.2 million as of December 31, 2025.<h2 class="st-heading-2">Segment Performance</h2>GRPN’s North America revenue was $98.7 million in the fourth quarter 2025, up 2% compared with the prior year period. Region’s gross billings were $323.8 million in the fourth quarter 2025, up 6% year-over-year.&nbsp;International revenue was $34.0 million in the fourth quarter 2025, up 1% compared with the prior year period. However, International gross billings were $122.7 million in the fourth quarter 2025, down 1% year-over-year. Excluding Giftcloud and Italy, International Local billings increased 16% in the quarter.&nbsp;International unit sales were 3.5 million in the fourth quarter 2025, up 21% sequentially and down 5% compared with the prior year period.&nbsp;<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>Retail sentiment around GRPN trended in ‘extremely bullish’ territory amid ‘extremely high’ message volume.&nbsp;Shares in the company have fallen 43.4% year-to-date.&nbsp;

Groupon's International gross billings were $122.7 million in the fourth quarter 2025, down 1% year-over-year. 

Groupon Stock Fell 11% After Hours – Here’s Why

The company said its revenue was $132.7 million in the fourth quarter 2025, below analyst expectations of $136.7 million, as per data from Fiscal.ai. 

iShares Trust - iShares Russell 2000 ETF

Up 5%

Down 5%

Show me the results

Which direction is the next 5% move for the S&amp;P 500?

Stocktwits

Which direction is the next 5% move for the S&P 500?

Stocktwits Polls

iShares Russell 2000 ETF

Traders are closely watching IWM's underperformance, as small-cap indices face deeper declines and questions arise about their resilience amid broader market challenges.

Escalating Middle East tensions and surging oil prices are driving significant market uncertainty, with the Strait of Hormuz situation front and center for traders.

Recent economic releases, including downward revised GDP and key inflation data, are fueling market anxiety and influencing expectations for future policy decisions.

Aggressive IWM options trading is surging, with active plays on calls and puts as traders eye critical technical levels and leverage extreme oversold RSI conditions.

IWM
iShares Russell 2000 ETF

Feed

News

Sentiment

Fundamentals

Info

Poll

Latest IWM News

IWMiShares Russell 2000 ETF